100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
MN553 / MN553: Advanced Pharmacology & Pharmacotherapeutics Unit 1 Quiz Questions & Answers R133,00
Add to cart
Quickly navigate to
Preview
  2.  
  3. University Of South Africa (Unisa)
  4.  
  5. MN553

Exam (elaborations)

MN553 / MN553: Advanced Pharmacology & Pharmacotherapeutics Unit 1 Quiz Questions & Answers
 7 views  0 purchase

MN553 / MN553: Advanced Pharmacology & Pharmacotherapeutics Unit 1 Quiz Questions & Answers

Preview 4 out of 139  pages

Document information

  • February 11, 2022
  • 139
  • 2021/2022
  • Exam (elaborations)
  • Questions & answers

Subjects

  • mn553 mn553 advanced pharmacology amp pharmacotherapeutics unit 1 quiz questions amp answers

Written for

All documents for this subject (1)

Seller

avatar-seller
UNISA1

Content preview

Chapter i1. iThe iRole iof ithe iNurse iPractitioner

Multiple iChoice
Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion.

i 1. Nurse ipractitioner iprescriptive iauthority iis iregulated iby:
1 The iNational iCouncil iof iState iBoards iof iNursing
.
2 The iU.S. iDrug iEnforcement iAdministration
.
3 The iState iBoard iof iNursing ifor ieach istate
.
4 The iState iBoard iof iPharmacy
.

i 2. The ibenefits ito ithe ipatient iof ihaving ian iAdvanced iPractice iRegistered iNurse i(APRN) iprescriber iinclude:
1 Nurses iknow imore iabout iPharmacology ithan iother iprescribers ibecause ithey itake
. iit iboth iin itheir ibasic inursing iprogram iand iin itheir iAPRN iprogram.

2 Nurses icare ifor ithe ipatient ifrom ia iholistic iapproach iand iinclude ithe ipatient iin
. decision imaking iregarding itheir icare.
3 APRNs iare iless ilikely ito iprescribe inarcotics iand iother icontrolled isubstances.
.
4 APRNs iare iable ito iprescribe iindependently iin iall istates, iwhereas ia iphysician’s
. assistant ineeds ito ihave ia iphysician isupervising itheir ipractice.

i 3. Clinical ijudgment iin iprescribing iincludes:
1 Factoring iin ithe icost ito ithe ipatient iof ithe imedication iprescribed
.
2 Always iprescribing ithe inewest imedication iavailable ifor ithe idisease iprocess
.
3 Handing iout idrug isamples ito ipoor ipatients
.
4 Prescribing iall igeneric imedications ito icut icosts
.

i 4. Criteria ifor ichoosing ian ieffective idrug ifor ia idisorder iinclude:
1. Asking ithe ipatient iwhat idrug ithey ithink iwould iwork ibest ifor ithem
2. Consulting inationally irecognized iguidelines ifor idisease imanagement
3. Prescribing imedications ithat iare iavailable ias isamples ibefore iwriting ia
iprescription

4. Following iU.S. iDrug iEnforcement iAdministration iguidelines ifor iprescribing

i 5. Nurse ipractitioner ipractice imay ithrive iunder ihealth-care ireform ibecause iof:
1 The idemonstrated iability iof inurse ipractitioners ito icontrol icosts iand iimprove
. patient ioutcomes
2 The ifact ithat inurse ipractitioners iwill ibe iable ito ipractice iindependently
.
3 The ifact ithat inurse ipractitioners iwill ihave ifull ireimbursement iunder ihealth-care
. reform
4 The iability ito ishift iaccountability ifor iMedicaid ito ithe istate ilevel
.



Chapter i2. iReview iof iBasic iPrinciples iof iPharmacology

Multiple iChoice
Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe iquestion.

i 1. A ipatient’s inutritional iintake iand ilaboratory iresults ireflect ihypoalbuminemia. iThis iis icritical ito iprescribing ibecause:
1 Distribution iof idrugs ito itarget itissue imay ibe iaffected.
.

, 2 The isolubility iof ithe idrug iwill inot imatch ithe isite iof iabsorption.
.
3 There iwill ibe iless ifree idrug iavailable ito igenerate ian ieffect.
.
4 Drugs ibound ito ialbumin iare ireadily iexcreted iby ithe ikidneys.
.

i 2. Drugs ithat ihave ia isignificant ifirst-pass ieffect:
1 Must ibe igiven iby ithe ienteral i(oral) iroute ionly
.
2 Bypass ithe ihepatic icirculation
.
3 Are irapidly imetabolized iby ithe iliver iand imay ihave ilittle iif iany idesired iaction
.
4 Are iconverted iby ithe iliver ito imore iactive iand ifat-soluble iforms
.


i 3. The iroute iof iexcretion iof ia ivolatile idrug iwill ilikely ibe ithe:
1 Kidneys
.
2 Lungs
.
3 Bile iand ifeces
.
4 Skin
.

i 4. Medroxyprogesterone i(Depo iProvera) iis iprescribed iintramuscularly i(IM) ito icreate ia istorage ireservoir iof ithe idrug.
Storage ireservoirs:
1 Assure ithat ithe idrug iwill ireach iits iintended itarget itissue
.
2 Are ithe ireason ifor igiving iloading idoses
.
3 Increase ithe ilength iof itime ia idrug iis iavailable iand iactive
.
4 Are imost icommon iin icollagen itissues
.

i 5. The iNP ichooses ito igive icephalexin ievery i8 ihours ibased ion iknowledge iof ithe idrug’s:
1 Propensity ito igo ito ithe itarget ireceptor
.
2 Biological ihalf-life
.
3 Pharmacodynamics
.
4 Safety iand iside ieffects
.

i 6. Azithromycin idosing irequires ithat ithe ifirst iday’s idosage ibe itwice ithose iof ithe iother i4 idays iof ithe iprescription. iThis
isiconsidered ia iloading idose. iA iloading idose:
i

1 Rapidly iachieves idrug ilevels iin ithe itherapeutic irange
.
2 Requires ifour- ito ifive-half-lives ito iattain
.
3 Is iinfluenced iby irenal ifunction
.
4 Is idirectly irelated ito ithe idrug icirculating ito ithe itarget itissues
.

i 7. The ipoint iin itime ion ithe idrug iconcentration icurve ithat iindicates ithe ifirst isign iof ia itherapeutic ieffect iis ithe:
1 Minimum iadverse ieffect ilevel
.
2 Peak iof iaction

, .
3 Onset iof iaction
.
4 Therapeutic irange
.

i 8. Phenytoin irequires ithat ia itrough ilevel ibe idrawn. iPeak iand itrough ilevels iare idone:
1 When ithe idrug ihas ia iwide itherapeutic irange
.
2 When ithe idrug iwill ibe iadministered ifor ia ishort itime ionly
.
3 When ithere iis ia ihigh icorrelation ibetween ithe idose iand isaturation iof ireceptor isites
.
4 To idetermine iif ia idrug iis iin ithe itherapeutic irange
.

i 9. A ilaboratory iresult iindicates ithat ithe ipeak ilevel ifor ia idrug iis iabove ithe iminimum itoxic iconcentration. iThis imeans
i thatithe:
1 Concentration iwill iproduce itherapeutic ieffects
.
2 Concentration iwill iproduce ian iadverse iresponse
.
3 Time ibetween idoses imust ibe ishortened
.
4 Duration iof iaction iof ithe idrug iis itoo ilong
.

i 10. Drugs ithat iare ireceptor iagonists imay idemonstrate iwhat iproperty?
1 Irreversible ibinding ito ithe idrug ireceptor isite
.
2 Upregulation iwith ichronic iuse
.
3 Desensitization ior idownregulation iwith icontinuous iuse
.
4 Inverse irelationship ibetween idrug iconcentration iand idrug iaction
.

i 11. Drugs ithat iare ireceptor iantagonists, isuch ias ibeta iblockers, imay icause:
1 Downregulation iof ithe idrug ireceptor
.
2 An iexaggerated iresponse iif iabruptly idiscontinued
.
3 Partial iblockade iof ithe ieffects iof iagonist idrugs
.
4 An iexaggerated iresponse ito icompetitive idrug iagonists
.

i 12. Factors ithat iaffect igastric idrug iabsorption iinclude:
1 Liver ienzyme iactivity
.
2 Protein-binding iproperties iof ithe idrug imolecule
.
3 Lipid isolubility iof ithe idrug
.
4 Ability ito ichew iand iswallow
.

i 13. Drugs iadministered ivia iIV:
1 Need ito ibe ilipid isoluble iin iorder ito ibe ieasily iabsorbed
.
2 Begin idistribution iinto ithe ibody iimmediately
.
3 Are ieasily iabsorbed iif ithey iare inonionized
.

, 4 May iuse ipinocytosis ito ibe iabsorbed
.

i 14. When ia imedication iis iadded ito ia iregimen ifor ia isynergistic ieffect, ithe icombined ieffect iof ithe idrugs iis:
1 The isum iof ithe ieffects iof ieach idrug iindividually
.
2 Greater ithan ithe isum iof ithe ieffects iof ieach idrug iindividually
.
3 Less ithan ithe ieffect iof ieach idrug iindividually
.
4 Not ipredictable, ias iit ivaries iwith ieach iindividual
.

i 15. Which iof ithe ifollowing istatements iabout ibioavailability iis itrue?
1 Bioavailability iissues iare iespecially iimportant ifor idrugs iwith inarrow itherapeutic
. ranges ior isustained-release imechanisms.
2 All ibrands iof ia idrug ihave ithe isame ibioavailability.
.
3 Drugs ithat iare iadministered imore ithan ionce ia iday ihave igreater ibioavailability
. than idrugs igiven ionce idaily.
4 Combining ian iactive idrug iwith ian iinert isubstance idoes inot iaffect ibioavailability.
.

i 16. Which iof ithe ifollowing istatements iabout ithe imajor idistribution ibarriers i(blood-brain ior ifetal-placental) iis itrue?
1 Water isoluble iand iionized idrugs icross ithese ibarriers irapidly.
.
2 The iblood-brain ibarrier islows ithe ientry iof imany idrugs iinto iand ifrom ibrain icells.
.
3 The ifetal-placental ibarrier iprotects ithe ifetus ifrom idrugs itaken iby ithe imother.
.
4 Lipid-soluble idrugs ido inot ipass ithese ibarriers iand iare isafe ifor ipregnant iwomen.
.

i 17. Drugs iare imetabolized imainly iby ithe iliver ivia iphase iI ior iphase iII ireactions. iThe ipurpose iof iboth iof ithese itypes
i of ireactions iis ito:
1 Inactivate iprodrugs ibefore ithey ican ibe iactivated iby itarget itissues
.
2 Change ithe idrugs iso ithey ican icross iplasma imembranes
.
3 Change idrug imolecules ito ia iform ithat ian iexcretory iorgan ican iexcrete
.
4 Make ithese idrugs imore iionized iand ipolar ito ifacilitate iexcretion
.

i 18. Once ithey ihave ibeen imetabolized iby ithe iliver, ithe imetabolites imay ibe:
1. More iactive ithan ithe iparent idrug
2. Less iactive ithan ithe iparent idrug
3. Totally i“deactivated” iso itheyiare iexcreted iwithout ianyieffect
4. All iof ithe iabove

i 19. All idrugs icontinue ito iact iin ithe ibody iuntil ithey iare ichanged ior iexcreted. iThe iability iof ithe ibody ito iexcrete idrugs ivia
the irenal isystem iwould ibe iincreased iby:
i

1 Reduced icirculation iand iperfusion iof ithe ikidney
.
2 Chronic irenal idisease
.
3 Competition ifor ia itransport isite iby ianother idrug
.
4 Unbinding ia inonvolatile idrug ifrom iplasma iproteins
.

i 20. Steady istate iis:
1. The ipoint ion ithe idrug iconcentration icurve iwhen iabsorption iexceeds iexcretion
2. When ithe iamount iof idrug iin ithe ibody iremains iconstant

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through EFT, credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying this summary from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller UNISA1. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy this summary for R133,00. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

53022 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy summaries for 14 years now

Start selling
R133,00
  • (0)
Add to cart
Added